Home›Companies›Biotech & Pharma›Altesa BioSciences

Altesa BioSciences, Inc.

Develops an oral antiviral medicine for people with chronic lung disease.

Updated Nov 11, 2026·Latest SEC filing Feb 23, 2026·Suggest an edit

About Altesa BioSciences

Altesa BioSciences is a private company based in College Park, Georgia. It has reported $109,999,986 raised in two offerings on Form D since January 2023.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Feb 13, 2026Feb 23, 2026$74,999,986fully sold17$4.4MEquityRule 506(b)Form D ↗
Dec 22, 2022Jan 5, 2023amended Jul 7, 2023$35,000,000fully sold18$1.9MEquityRule 506(b)Form D/A ↗1 earlier filing
Total, two offerings$109,999,986

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Altesa BioSciences's Form D filed Feb 23, 2026.

John Clerici
John Clerici
President and Chief Operating Officer
AD
Seth Rudnick
Seth Rudnick
Altesa Co-Founder and director
Brett Giroir
Brett Giroir
Executive officer and director
Also a chairman & interim CEO at OncoNano.
Ittai Harel
Ittai Harel
Managing and director
Also a director at HomeThrive and Vertos Medical.

Sources

  1. SECAltesa BioSciences, Inc. Form D, filed Jan 5, 2023
  2. SECAltesa BioSciences, Inc. filing history
  3. CompanyLeadership
  4. PressAltesa BioSciences Series B announcement